Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (ATNM)
NYSE MKT:ATNM
RESEARCH TOOLSreports
Holding ATNM?
Track your performance easily
ATNM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.33 - $10.24
Previous Close$1.39
Volume277.83K
Average Volume (3M)302.46K
Market Cap
$44.30M
Enterprise Value-$32.65M
Total Cash (Recent Filing)$78.66M
Total Debt (Recent Filing)$1.71M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Mar 14, 2025EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding31,195,891
10 Day Avg. Volume301,879
30 Day Avg. Volume302,456
Standard Deviation0.25
R-Squared0.00093
Alpha0.00578
Financial Highlights & Ratios
Price to Book (P/B)1.14
Price to Sales (P/S)546.89
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-403.10
Enterprise Value/Gross Profit-403.10
Enterprise Value/Ebitda0.78
Forecast
1Y Price Target
$4.67Price Target Upside217.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Actinium Pharmaceuticals News
PremiumCompany Announcements
Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress
PremiumCompany Announcements
Actinium Pharmaceuticals Strengthens Board with New Appointment
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe trial met its primary endpoint of 6-month durable complete remission (dCR), as well as its secondaries.
Pipeline AdvancementPositive data from the completed P1b combination trial of Actimab-A + CLAG-M showed high rates of response, measurable residual disease negativity, bone marrow transplant access, and improved survival outcomes in high-risk patients.
Regulatory ProgressActinium announced FDA clearance for an IND to study Iomab-ACT as targeted conditioning before CAR-T therapy and for BMT for sickle cell patients.
Bears Say
Financial PerformanceDecreasing the terminal growth rate used in the risk-adjusted discounted cash flow analysis from 2% to -5% to reflect potential headwinds and uncertainty following deprioritization of Iomab-B development.
Regulatory ChallengesThe FDA determined that the SIERRA trial design and analysis are inadequate, and an overall survival benefit in a randomized head-to-head trial would be required for a BLA.
Strategic PartnershipsATNM does not plan to fund the late-stage Iomab-B trial now required for BLA filing at this time and will instead search for amenable U.S. partners.
---
Ownership Overview
6.13%
Insiders
8.21% Mutual Funds
1.56% Other Institutional Investors
75.15% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATNM FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $1.33 and its highest was $10.24 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Currently, no data Available
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Mar 14, 2025 which is in 112 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Nov 18, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.385 by $0.015.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate is -$0.39.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,195,890 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.385. Following the earnings report the stock price went down -5.333%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Among the largest hedge funds holding Actinium Pharmaceuticals’s share is Royce & Associates LLC. It holds Actinium Pharmaceuticals’s shares valued at 94K.
---
Actinium Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (217.69% Upside)
$4.67 (217.69% Upside)
Blogger Sentiment
Bullish
ATNM Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.65%
12-Months-Change
Fundamentals
Return on Equity
-100.05%
Trailing 12-Months
Asset Growth
-7.68%
Trailing 12-Months
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
---
ATNM Stock 12 Month Forecast
Average Price Target
$4.67
▲(217.69% Upside)
Technical Analysis
Best Analysts Covering ATNM
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-49.02%
reiterated a buy rating 4 months ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -49.02% per trade.
---